Your browser doesn't support javascript.
loading
[Research progress on Chinese medicinal material-derived active polypeptides against ischemic cardiovascular and cerebrovascular diseases].
Wang, Ao-Ao; Li, Lei; Li, Ying; Miao, Lan; Pan, Ying-Hong; Liu, Jian-Xun.
Afiliação
  • Wang AA; National Clinical Research Center of Traditional Chinese Medicine for Cardiovascular Diseases, Beijing Key Laboratory of Chinese Materia Pharmacology, Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
  • Li L; National Clinical Research Center of Traditional Chinese Medicine for Cardiovascular Diseases, Beijing Key Laboratory of Chinese Materia Pharmacology, Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
  • Li Y; National Clinical Research Center of Traditional Chinese Medicine for Cardiovascular Diseases, Beijing Key Laboratory of Chinese Materia Pharmacology, Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
  • Miao L; National Clinical Research Center of Traditional Chinese Medicine for Cardiovascular Diseases, Beijing Key Laboratory of Chinese Materia Pharmacology, Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
  • Pan YH; Institute of Crop Sciences, Chinese Academy of Agricultural Sciences Beijing 100081, China.
  • Liu JX; National Clinical Research Center of Traditional Chinese Medicine for Cardiovascular Diseases, Beijing Key Laboratory of Chinese Materia Pharmacology, Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
Zhongguo Zhong Yao Za Zhi ; 46(21): 5576-5584, 2021 Nov.
Article em Zh | MEDLINE | ID: mdl-34951209
ABSTRACT
Ischemic cardiovascular and cerebrovascular diseases threatening human health and survival have high morbidity and mortality. The common cause of them is reduced blood supply caused by vascular stenosis, atherosclerosis, and infarction. However,the pathological processes of ischemic cardiovascular and cerebrovascular diseases are complex, involving oxidative stress, calcium overload, inflammation, apoptosis, autophagy and other mechanisms. Protein drugs such as recombinant tissue plasminogen activator(rt-PA) and urokinase have been proved with excellent therapeutic effects and huge economic and social benefits in the clinical treatment and interventional therapy. Among them, peptide drugs have shown unique advantages and potential prospects owing to their strong biological activity, high target specificity, biochemical diversity, and low toxicity. Chinese medicinal materials, characterized by multi-component and multi-target therapy, have also shown excellent clinical efficacy against ischemic cardiovascular and cerebrovascular diseases. However, the research and development of related peptides in Chinese medicinal materials is at the initial stage. Therefore, this paper reviewed the targets and action mechanisms of a variety of Chinese medicinal material-derived polypeptides with activities against ischemic cardiovascular and cerebrovascular diseases, aiming to provide support for the in-depth research as well as the clinical development and application of these polypeptides.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Medicinas Tradicionais: Medicinas_tradicionales_de_asia / Medicina_china Métodos Terapêuticos e Terapias MTCI: Terapias_biologicas Assunto principal: Medicamentos de Ervas Chinesas / Transtornos Cerebrovasculares Tipo de estudo: Diagnostic_studies País/Região como assunto: Asia Idioma: Zh Revista: Zhongguo Zhong Yao Za Zhi Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Base de dados: MEDLINE Medicinas Tradicionais: Medicinas_tradicionales_de_asia / Medicina_china Métodos Terapêuticos e Terapias MTCI: Terapias_biologicas Assunto principal: Medicamentos de Ervas Chinesas / Transtornos Cerebrovasculares Tipo de estudo: Diagnostic_studies País/Região como assunto: Asia Idioma: Zh Revista: Zhongguo Zhong Yao Za Zhi Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China